- Home
- IMVT vs NAMS Comparison
IMVT vs NAMS Comparison
Compare IMVT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- NAMS
- Stock Information
- Founded
- IMVT 2018
- NAMS 2019
- Country
- IMVT United States
- NAMS Netherlands
- Employees
- IMVT N/A
- NAMS N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- IMVT Health Care
- NAMS Health Care
- Exchange
- IMVT Nasdaq
- NAMS Nasdaq
- Market Cap
- IMVT 2.7B
- NAMS 3.1B
- IPO Year
- IMVT N/A
- NAMS N/A
- Fundamental
- Price
- IMVT $16.00
- NAMS $32.22
- Analyst Decision
- IMVT Buy
- NAMS Strong Buy
- Analyst Count
- IMVT 10
- NAMS 9
- Target Price
- IMVT $33.38
- NAMS $41.89
- AVG Volume (30 Days)
- IMVT 1.7M
- NAMS 987.3K
- Earning Date
- IMVT 11-06-2025
- NAMS 11-05-2025
- Dividend Yield
- IMVT N/A
- NAMS N/A
- EPS Growth
- IMVT N/A
- NAMS N/A
- EPS
- IMVT N/A
- NAMS N/A
- Revenue
- IMVT N/A
- NAMS $64,006,000.00
- Revenue This Year
- IMVT N/A
- NAMS N/A
- Revenue Next Year
- IMVT N/A
- NAMS $1.67
- P/E Ratio
- IMVT N/A
- NAMS N/A
- Revenue Growth
- IMVT N/A
- NAMS 762.15
- 52 Week Low
- IMVT $12.72
- NAMS $14.06
- 52 Week High
- IMVT $32.10
- NAMS $34.62
- Technical
- Relative Strength Index (RSI)
- IMVT 50.79
- NAMS 73.32
- Support Level
- IMVT $15.81
- NAMS $27.15
- Resistance Level
- IMVT $17.15
- NAMS $34.59
- Average True Range (ATR)
- IMVT 0.73
- NAMS 1.56
- MACD
- IMVT 0.10
- NAMS 0.54
- Stochastic Oscillator
- IMVT 57.98
- NAMS 77.28
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.